Blood
Articles in this Issue
Burger JA, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. <i>Blood.</i> 2025;146(18):2168-2176.
Ready, set, GO? Treating older adults with AML
Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia
Abstract Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) depend on oxidative phosphorylation (OXPHOS) sustained by fatty acid oxidation (FAO) and mitochondrial fusion (m...
Introduction to a review series on hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of life-threatening hyperinflammation that challenges pediatric and adult hematologists. Deputy Editors Helen E. Heslop and Jorge Di Paola introd...
Tuning mitochondrial fate to disarm leukemic stem cells
PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Abstract Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) c...
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial
Abstract We compared daunorubicin/cytarabine plus fractionated gemtuzumab ozogamicin (DAGO2) with CPX-351 (CPX; 1:2 randomization) in 439 patients with acute myeloid leukemia (AML)...
IFN-γ/JAK/STAT axis awakens the delta force of hemoglobin
Could a TCR be faster than a CAR?
Targeting BCMA: a double-edged sword for infection risk
A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies
Abstract CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in relapse and/or refractory B-cell malignancies. Up to 30% to 60% of patients experien...
Focal MPN-associated <i>JAK2-</i> mutated skeletal lesion with normal blood counts and bone marrow
Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment
Abstract Pediatric hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome, characterized by heightened T-cell activation and overwhelming interfe...
Hemophagocytic lymphohistiocytosis in adults
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hematologic disorder characterized by unchecked immune activation and hyperinflammation, resulting in end-or...
MRD is a new therapeutic target in AML
Pretransplant promise for PD-1 in Hodgkin lymphoma
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
Abstract Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti–B-cell maturation antigen (BCMA) and anti–G protein-coupled receptor class...
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Abstract Measurable residual disease (MRD) can predict relapse in patients with advanced myelodysplastic neoplasms (MDS) or acute myeloid leukemia (AML). We report the long-term ef...
IFN-γ increases δ-globin gene expression through activation of the JAK/STAT pathway in erythroid cells
Abstract Sickle cell disease (SCD) and β-thalassemia, caused by mutations or deletions in the β-globin gene, are among the most prevalent genetic disorders worldwide, significantly...